MTOR and hepatocellular carcinoma: Recent research found that FSTL1 mainly derived from CAFs in human HCC could promote tumor growth, metastasis, and therapy resistance by activating AKT/mTOR/4EBP1/c-myc pathway via binding to toll-like receptors 4 (TLR4) on HCC cells (92).